Exclusive Physician Survey Results on GLP-1 Receptor Agonists: The Hype Is Real
October 22, 2024

Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.

The Legacy of Vaccine Hesitancy: From COVID-19 to Flu
October 22, 2024

Vaccine hesitancy became a public health threat during the COVID-19 pandemic that lingers now and has affected uptake of other essential immunizations.

Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults
October 21, 2024

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting
October 21, 2024

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Novel PACAP-Targeted Antibody Reduces Monthly Migraine Days in Phase 2 HOPE Trial
October 21, 2024

A single 750 mg intravenous infusion of Lu AG09222 showed a 2-day difference in reducing monthly migraine day compared with placebo.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial
October 21, 2024

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Atopic Dermatitis is Not "Just" Eczema: Disease Primer with Mona Shahriari, MD
October 21, 2024

Dermatology thought leader Mona Shihriari, MD, offers a brief overview of the inflammatory skin disease for primary care clinicians.

IDWeek 2024: Novavax Reports Positive Data for Novel Influenza and Flu-COVID-19 Combination Vaccines
October 18, 2024

IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.

IDWeek 2024: Merck’s 21-Valent Pneumococcal Vaccine Shows Positive Immune Responses in At-Risk Adults
October 18, 2024

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.

7 Factors That Lead Americans to Skip Health Screening
October 18, 2024

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.